Delivering novel therapeutics for the treatment of autoimmune diseases
SuppreMol, a privately held biopharmaceutical Company, is developing novel proteins to treat autoimmune diseases. SuppreMol has developed a novel therapeutic concept for the treatment of autoimmune diseases that relies on naturally produced Fc gamma receptors (FcγRs). The Company was founded in 2002 as a spin-off from the Max Planck Institute of Biochemistry.
The Company is developing SM101 for the treatment of Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) in Phase II clinical trials. SM101 is designed to be a specific, early onset, long lasting and well tolerated treatment for autoimmune diseases such as ITP, SLE, Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS).
Further building its platform of selective immunoregulators, SuppreMol is working on antibody programs targeting Fc receptors and other immunomodulatory molecules for alternative treatment strategies in autoimmune conditions.